Our impact

Myeloma UK invests in innovative, life-changing research, advocates for patients to get access to new treatments on the NHS and provides free information and support services to patients and their families.

We are funded almost entirely by supporters like you – thank you!

Myeloma UK was established in 1997 to change the lives of patients with myeloma and related conditions and realise our ambition of making myeloma history.

Myeloma is a very individual blood cancer, and every patient’s experience is different.

When we first started our work

The average length of time a patient with myeloma could expect to survive was between 12 and 24 months.

Today, that time has quadrupled to between four to eight years, with three out of ten patients living for ten years or more after their diagnosis – and some for much longer still.

There were no bespoke myeloma treatments available to patients via the NHS.

Today, we have ten myeloma drugs in active use in the NHS pathway that can be delivered in 13 different combinations throughout a patient’s treatment journey.

That’s real progress, and it didn’t just happen – it was hard fought for thanks to support from people like you.

Your support powers us forward

Thanks to your support, in 2023 we:

Fighting for patients to get access to new treatments

We’re delighted that in March 2024, we won our #UnlockDaraCyBorD campaign, which asked the National Institute for Health and Care Excellence (NICE) to review its decision to reject the first bespoke AL amyloidosis treatment.

Up to 600 people each year will now benefit from the life-extending treatment, known as DaraCyBorD.

“This is tremendous news and means that, for the very first time, people who have AL amyloidosis will be able to gain access to this bespoke treatment. I want to extend my heartfelt thanks to everyone who has fought alongside us. Every person who has written to their MP, shared their story and helped us make the case to NICE about this significant unmet need and the huge impact it will have.”

Sophie Castell, CEO Myeloma UK

Investing in life-changing research

Thanks to your support, we can invest in pioneering research, like the MUK nine/OPTIMUM Clinical Trial.

The David Forbes-Nixon Foundation is supporting Myeloma UK through the Jaquelin Forbes-Nixon Research Fellowship which helps to fund one of the lead investigators, Dr Martin Kaiser, at the Institute of Cancer Research (ICR). The trial is exploring how to improve treatment for patients with the most aggressive, high-risk forms of myeloma. The results so far are extremely promising, and Dr Kaiser hopes that NHS will consider the data as soon as possible.

“To work together with Myeloma UK on research is fantastic.

It is a patient-centric charity, which means that these projects, which are really aiming to benefit patients are particularly prioritised, and I think we are really seeing the results of that coming through.”

Dr Martin Kaiser

Providing free information and support services

Last year alone, we answered 1,847 calls to our freephone Myeloma Infoline and replied to 941 emails from our Ask the Nurse email service, ensuring no one has to face myeloma alone. Our dedicated team of Myeloma Information Specialists provide information about myeloma and its treatments, practical advice and emotional support.

Thanks to you, these services are freely available, providing a lifeline for people affected by myeloma.

“I think the Infoline is first rate and I am so relieved that you continue to invest in having a telephone service. Myeloma and Amyloidosis are such isolating diseases and so stressful that it makes a world of a difference to speak to a person who understands and can help. Thank you so much Myeloma UK”

Myeloma Infoline user

“Together, with your support, we’ve achieved all of this and more.

Myeloma UK receives no Government funding – our work is powered by your generous donations, fundraising efforts and gifts in wills.

Thank you so much for your support – together we are working with myeloma patients to create an empowered present and a hopeful future.”

Sophie Castell, CEO Myeloma UK

Other ways you can get involved and make a difference

Donate and help fund our vital work

Whether you choose to make a one-off donation or give regularly, your gift will help to make sure no one faces myeloma alone.